Rapid-acting antidepressant for treatment-resistant depression: New insights
Researchers have generated fresh insights that could aid in the development of rapid-acting antidepressants for treatment-resistant depression. The researchers found that by blocking NMDA receptors with the drug ketamine, they could elicit rapid antidepressant effects in patients with treatment-resistant depression. Ketamine was developed as an anesthetic, but is better known publicly for its abuse as the party drug Special K. Researchers are now seeking alternatives because ketamine can produce side effects that include hallucinations and the potential for abuse -- limiting its utility as an antidepressant.
View full story